title: Efficacy and tolerability of cefditoren pivoxil in uncomplicated skin and skin structure infections in Indian patients.
abstract: BACKGROUND
  Uncomplicated skin and skin structure infections (uSSSI) are commonly encountered community-acquired infections and are typically confined to the superficial layers of the skin. Hence, they seldom lead to the destruction of skin structures.
  
  
  OBJECTIVE
  To evaluate the efficacy and tolerability of cefditoren pivoxil in uSSSI in Indian patients.
  
  
  METHODS
  One hundred and seventy-eight patients diagnosed with uncomplicated SSSI were enrolled in this randomized, comparative, multicentric study. Patients received either cefditoren pivoxil or cefdinir for ten days. Efficacy was assessed both clinically and microbiologically. Safety evaluation consisted of reporting of type, frequency, severity, and causal relationship of adverse events.
  
  
  RESULTS
  One hundred and fifty-one patients completed the study. Clinical and bacteriological efficacy of cefditoren pivoxil was comparable to that of cefdinir in the treatment of uSSSI. One hundred and five patients were eligible for per protocol (PP) analysis of bacteriological outcome and clinical efficacy. Clinical cure or improvement was achieved in 98.00% patients treated with cefditoren pivoxil and 98.18% patients treated with cefdinir. In the modified Intent to Treat (mITT) patient population, clinical cure or improvement was recorded in 97.33% patients treated with cefditoren pivoxil and 96.20% patients treated with cefdinir. Microbiological eradication (or presumed eradication) was recorded in 88.00% patients treated with cefditoren pivoxil and 94.55% patients treated with cefdinir. The above differences in the outcome rates between the two drugs were not statistically significant. Six adverse events (AEs) (two in cefditoren group and four in cefdinir group) were reported in this study.
  
  
  CONCLUSIONS
  Cefditoren pivoxil 200 mg b.i.d. was effective and well tolerated in the treatment of uSSSI.
authors.affiliation: Medical Affairs and Clinical Research, Ranbaxy Laboratories Ltd, 77-B, IFFCO Road, Sector-18, Udyog Vihar Industrial Area, Gurgaon, Haryana, India. charu.manaktala@ranbaxy.com
authors.forename: Charu
authors.initials: C
authors.lastname: Manaktala
authors.forename: Amit Kumar
authors.initials: AK
authors.lastname: Singh
authors.forename: Manish
authors.initials: M
authors.lastname: Verma
authors.forename: Asheesh
authors.initials: A
authors.lastname: Sachdeva
authors.forename: Himanshu
authors.initials: H
authors.lastname: Sharma
authors.forename: Arjun
authors.initials: A
authors.lastname: Roy
authors.forename: R K
authors.initials: RK
authors.lastname: Jalali
authors.forename: R
authors.initials: R
authors.lastname: Gowrishankar
authors.forename: A
authors.initials: A
authors.lastname: Kumar
authors.forename: A Sainath
authors.initials: AS
authors.lastname: Kumar
authors.forename: A M
authors.initials: AM
authors.lastname: Jayaraman
authors.forename: B
authors.initials: B
authors.lastname: Swarnkar
authors.forename: C R
authors.initials: CR
authors.lastname: Srinivas
authors.forename: Chitra
authors.initials: C
authors.lastname: Nayak
authors.forename: D
authors.initials: D
authors.lastname: Duttaroy
authors.forename: D
authors.initials: D
authors.lastname: Umrigar
authors.forename: Madhuri
authors.initials: M
authors.lastname: Jesudanam
authors.forename: N
authors.initials: N
authors.lastname: Maheshwari
authors.forename: P
authors.initials: P
authors.lastname: Shetty
authors.forename: R P
authors.initials: RP
authors.lastname: Singh
authors.forename: S
authors.initials: S
authors.lastname: Ghate
authors.forename: S
authors.initials: S
authors.lastname: Sacchidanand
authors.forename: S
authors.initials: S
authors.lastname: Tolat
authors.forename: Salman
authors.initials: S
authors.lastname: Bhoira
authors.forename: Y
authors.initials: Y
authors.lastname: Marfatia